What is ImmunityBio, Inc.'s AOCI?

ImmunityBio, Inc. (IBRX) reported AOCI of $27.45M in Q1 2026.

How has ImmunityBio, Inc.'s AOCI changed year-over-year?

ImmunityBio, Inc.'s AOCI increased by 37.6% year-over-year, from $19.96M to $27.45M.

What is the long-term trend for ImmunityBio, Inc.'s AOCI?

Over 5 years (2020 to 2025), ImmunityBio, Inc.'s AOCI has grown at a 198.6% compound annual growth rate (CAGR), from $122K to $28.96M.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

ImmunityBio, Inc. IBRX AOCI

AOCI at other companies

Bristol-Myers SquibbBMY

-$1.37B+3.8%

Johnson & JohnsonJNJ

-$14.83B-26.3%

Merck & Co.MRK

-$4.06B+18.2%

Gilead SciencesGILD

$78M-15.2%

Immunovant, Inc.IMVT

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s AOCI?: ImmunityBio, Inc. (IBRX) reported AOCI of $27.45M in Q1 2026.
How has ImmunityBio, Inc.'s AOCI changed year-over-year?: ImmunityBio, Inc.'s AOCI increased by 37.6% year-over-year, from $19.96M to $27.45M.
What is the long-term trend for ImmunityBio, Inc.'s AOCI?: Over 5 years (2020 to 2025), ImmunityBio, Inc.'s AOCI has grown at a 198.6% compound annual growth rate (CAGR), from $122K to $28.96M.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.